SL-401: An Encouraging Option for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Monday, June 6, 2016

Naveen Pemmaraju, MD, discusses early results from an ongoing trial of SL-401 in patients with the rare, aggressive malignancy blastic plasmacytoid dendritic cell neoplasm.

September 2020 Volume 6, Issue 11

August 2020 Volume 6, Issue 10

July 2020 Bonus Mid-Year Edition, Volume 6 Issue 9

July 2020 Volume 6, Issue 8

SL-401: An Encouraging Option for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Recent Articles

Moshe Mittelman, MD

Medical School Administrators Concerned About Insufficient Resources for Incoming Students

U.S. Officials Announce Plans for Coronavirus Vaccine

FDA Releases Comparative Performance Data for COVID-19 Diagnostic Tests

Megan Nakashima, MD

Current Issue

September 2020 Volume 6, Issue 11

Meeting Coverage

MLL Associated With Worse Post-Transplant Outcomes Than Other Cytogenetic Factors

Study Examines Trends in Real-World Treatment Sequencing Patterns for CLL/SLL

Editor's Corner

Editor’s Corner: What’s Your Type?

Editor’s Corner: The Zoombie Apocalypse